Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(antihemophilic factor recombinant Fc fusion protein)
89 results
  • Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits. [Review]
    Front Med (Lausanne). 2019; 6:261.Schiavoni M, Napolitano M, … Giordano P
  • The current interest in recombinant factor VIII (rFVIII) products stems from the fact that they offer a technological solution to prolonging the half-life of and reducing the risk of formation of alloantibodies (inhibitors) against FVIII in treated patients with hemophilia A (HA). The Italian health care system has authorized the use of a wide range of rFVIII concentrates of the first, second, an…
  • Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim? [Review]
    Front Immunol. 2019; 10:1196.Schifferli A, Nimmerjahn F, Kühne T
  • Fc fusion proteins and Fc fusion peptides or peptibodies are chimeric molecules composed of an active pharmacological protein or peptide and the Fc fragment of an immunoglobulin. The primary aim of this drug construct is to prolong the half-life of the active component. This molecular architecture is seen in drugs, such as etanercept, romiplostim, and the recombinant factor VIII (efmoroctocog alf…
  • rFVIIIFC for hemophilia A prophylaxis. [Review]
    Expert Rev Hematol. 2018 12; 11(12):937-943.Mahlangu J
  • Introduction: rFVIIIFC was the first extended half-life product to complete the phase 3 development program and be registered. It was developed to reduce the high treatment burden imposed by prophylaxis. It is now one of four extended half-life products available for a variety of indications in hemophilia A. This article focus on the efficacy use of rFVIIIFC in the prevention of bleeds in hemophi…
  • Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization. [Journal Article]
    Blood Adv. 2018 11 13; 2(21):2904-2916.Kis-Toth K, Rajani GM, … Loh C
  • The main complication of replacement therapy with factor in hemophilia A (HemA) is the formation of inhibitors (neutralizing anti-factor VIII [FVIII] antibodies) in ∼30% of severe HemA patients. Because these inhibitors render replacement FVIII treatment essentially ineffective, preventing or eliminating them is of top priority in disease management. The extended half-life recombinant FVIII Fc fu…
  • Prevention and Management of Bleeding Episodes in Children with Hemophilia. [Review]
    Paediatr Drugs. 2018 Oct; 20(5):455-464.Ljung RCR
  • Regular prophylactic treatment with factor VIII (FVIII) and factor IX (FIX) concentrates in hemophilia A and B, respectively, is introduced in early infancy and has resulted in dramatic improvement of the conditions. Recombinant FVIII and FIX concentrates have been available for > 25 years and have been modified and refined through the years; however, unfortunately frequent intravenous administra…
  • Recombinant factor VIII: past, present and future of treatment of hemophilia A. [Review]
    Drugs Today (Barc). 2018 Apr; 54(4):269-281.Raso S, Hermans C
  • The development of recombinant factor VIII (rFVIII) was initially driven by the necessity to treat hemophilia A (HA) patients with FVIII concentrates without the risk of transmitting infectious agents. Over the last three decades the safety of rFVIII has been further improved by completely removing animal or human proteins from the manufacturing process, so that patients would not be exposed to k…
  • Evolving Complexity in Hemophilia Management. [Review]
    Pediatr Clin North Am. 2018 06; 65(3):407-425.Croteau SE
  • Rapid expansion of therapeutic options have increased the complexity of hemophilia care. Previously, on-demand therapy aimed to reduce morbidity and early mortality; however, now aggressive prophylaxis, particularly in children, encourages an active lifestyle. Accurate diagnosis, recognition of early threats to musculoskeletal health, and optimization of therapy are critical for both males and fe…
  • Defining extended half-life rFVIII-A critical review of the evidence. [Review]
    Haemophilia. 2018 May; 24(3):348-358.Mahlangu J, Young G, … Santagostino E
  • CONCLUSIONS: In this systematic review, a pragmatic definition of EHL rFVIII has been proposed that should provide better clarity in clinical discussions surrounding the appropriate use of rFVIII products. At present, only products using PEGylation or Fc fusion half-life extension technology meet the proposed criteria for definition of EHL rFVIII.
  • Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia [Review]
    Blood. 2018 05 17; 131(20):2205-2214.Blumberg RS, Lillicrap D, IgG Fc Immune Tolerance Group
  • Hemophilia, or inherited genetic deficiencies in coagulation factors, results in uncontrolled bleeding requiring replacement therapy with recombinant proteins given preventively or on demand. However, a major problem with these approaches is the potential for development of immune responses to the administered proteins due to the underlying genetic deficiency of the factor(s) throughout life. As …
New Search Next